Advertisement

Topics

Latest "Mifepristone Cushing Syndrome" News Stories

21:53 EDT 3rd May 2016 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,000+

Extremely Relevant

Orphan designation: Mifepristone, for the: Treatment of hypercortisolism (Cushing’s syndrome) of endogenous origin


Children cured of Cushing syndrome still need mental health screening

Primary care physicians caring for children who have been successfully treated for Cushing syndrome should continue screening for mental illness, according to data published in Pediatrics.In an NIH study, the researchers found what they called the first documented evidence of suicide ideation in a subgroup of children and adolescents in remission of Cushing syndrome.

VIDEO: Cushing's syndrome still difficult to diagnose

BOSTON — In this video exclusive, Hershel Raff, PhD, professor of medicine, surgery and physiology at the Medical College of Wisconsin and scientific director and clinical research supervisor at Aurora St. Luke’s Medical Center, discusses his presentation on the laboratory diagnosis of Cushing’s syndrome. According to Raff, Cushing’s syndrome is the most enigmatic disease in endocrinology ...


A genetic and molecular update on adrenocortical causes of Cushing syndrome

Here, Lodish and Stratakis discuss the genetic mutations that give rise to Cushing syndrome, specifically those leading to the dysregulation of cAMP-dependent protein kinase A signalling. The authors also highlight how ARMC5 mutations contribute to adrenocortical hyperplasia, and discuss the role of this knowledge in patient care.

Children with Cushing syndrome may have higher suicide risk

Children with Cushing syndrome may be at higher risk for suicide as well as for depression, anxiety and other mental health conditions long after their disease has been successfully treated, according to a study by researchers at the National Institutes of Health.

Cushing's sx described in infant treated with ophthalmic steroid

(HealthDay)—In a case report published online April 7 in Pediatrics, iatrogenic Cushing's syndrome (ICS) is described in an infant following intranasal usage of dexamethasone ophthalmic solution.

Relevant

Neurosurgery TV Hangout today at 2 pm: “Life and Times of Harvey Cushing M.D”

Yes, Harvey Cushing MD was a Neurosurgeon Most people in medicine are acquainted with the name Cushing, but it is not widely known that he was a Neurosurgeon.  And he even rubbed shoulders with other surgical gods, like Osler and Halsted. Slaven Gojkovic, and 3rd year medical student in Croatia, […]

Author Uses Humor to Cope with Rare-Disease Diagnosis

HARRISBURG, Pa. (PRWEB) April 08, 2016 Hoping to help other Cushing’s disease patients and their families, Marie Conley releases her funny, intimate and emotional email exchanges with family and friends in the new book, “ A Cushing’s Collection: A Humorous Journey Surviving Cushing’s Diseas...

Strongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome

DUBLIN, Ireland and TREVOSE, Pa., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP) today announced that the United States Patent and Trademark Office (USPTO) issued a patent related to the Company's lead investigational drug candidate, COR-003 (levoketoconazole), a cortisol inhibitor that is currently being studied in a global Phase 3 trial for the treatment of endogenous...

UPDATE 8-Oil slides on new Cushing builds, global growth worry

* Latest Cushing crude stocks above 67.5 mln bbls - Genscape data

VIDEO: Late diagnosis of Cushing's disease still a problem

BOSTON — Maria Fleseriu, MD, FACE, professor of medicine and neurologic surgery at Oregon Health Sciences University, discusses her presentation on Cushing’s disease and treatment selection. According to Fleseriu, even 100 years after the discovery of Cushing’s disease, clinicians still struggle with late diagnosis of patients.

Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer

MENLO PARK, CA -- (Marketwired) -- 12/14/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating activity at the glucocorticoid receptor (GR), presented initial efficacy data from its Phase 1/2 trial of mifepristone in combina...

HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively low […]

Corcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial Results, Provides 2016 Revenue Guidance and Corporate Update

MENLO PARK, CA -- (Marketwired) -- 01/28/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported its preliminary financial results for t...

Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers

MENLO PARK, CA -- (Marketwired) -- 04/28/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today released data supporting the clinical advancement of its proprietary, selective cortisol modulator...

Corcept Therapeutics Announces 2015 Financial Results

MENLO PARK, CA -- (Marketwired) -- 03/01/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported its financial results for the fourth qu...

Stifel starts Strongbridge Biopharma at buy

Stifel has initiated coverage of Strongbridge Biopharma plc (NASDAQ:SBBP), formerly Cortendo plc, with a “buy” rating and a $21 target price. The stock closed at $7.49 on Monday. Strongbridge is an endocrinology-focused company, pursuing an acquisition model to build a diversified orphan-drug platform. “With a focus on rare endocrine diseases – Cushing’s syndrome and acromegaly [R...

Mifepristone: Additional Phase I/II data

Positive attitudes prevail within families of people with Down syndrome

Within most families, the experience of having a member with Down syndrome is generally a positive one, new research concludes. Investigators evaluated surveys of more than 2,000 parents or guardians of individuals with Down syndrome; more than 800 siblings of someone with Down syndrome, and 248 people with Down syndrome.

Attorney Michael Cushing Settles Wrongful Death Suit

Michael Cushing, a personal injury attorney at Cushing Law Offices, recently settled a wrongful death lawsuit (Case No. 12 L 897) on behalf of the family of a woman who died from drug intoxication that included Fentanyl, and a combination of other drugs. Chicago, IL (PRWEB) January 05, 2016 The wrongful death lawsuit, Fred Saltzman, as Special Administrator of the Estate of Tenessa Vincent, decea...

Corcept Therapeutics (CORT) Q3-2015 Update

On Thursday, November 5, 2015, Corcept Therapeutics (CORT) announced its results for Q3 2015 and held a conference call.

Mifepristone-inducible transgene expression in neural progenitor cells in vitro and in vivo

Corcept Therapeutics Advances Next Generation Drug into Multiple Trials

On April 28, 2016, Corcept Therapeutics (CORT) announced an update of its next generation, selective GR antagonist: CORT125134.       Launched Phase I/II Trial of CORT125134 to treat solid tumors     Will launch Phase II Trial of CORT125134 to treat Cushing’s syndrome in Q2-2016     Underscored CORT125134’s promising profile as seen in animal m...

An Advance Guide to Corcept's Corporate Update

On Thursday, January 28, 2015, Corcept Therapeutics’ (CORT), Corcept will release preliminary Q4-2015 results and provide guidance and corporate update.  Since 2014, Corcept has been providing a major update in January. The conference call details are below:When:   5:00pm, January 28, 2015Phone:  1-888-771-4371 (USA) & 1-847-585-4405 (International)    ...

SYNDROME de TAKOTSUBO: Quand le bonheur devient trop fort en émotion - The European Heart Journal

Takotsubo, c'est le nom d'un piège à poulpes japonais*. Sa forme a inspiré le nom du syndrome de Takotsubo. Un syndrome généralement provoqué par des facteurs de stress négatifs tels que la douleur, la colère, la peur : c'est le « syndrome du cœur brisé ».


Quick Search
Advertisement
 

News Quicklinks